Lymph node ratio and preoperative CA 19-9 levels predict overall survival and recurrence-free survival in patients with resected pancreatic adenocarcinoma

Table 4 Hazard ratios of clinicopathologic variables analyzed on univariate analysis for overall survival and recurrence-free survival

	Overall survival			Recurrence-free survival
	HR	95% CI	P value	HR	95% CI	P value
Age at surgery (73 yr vs 57.2 yr)	1.43	1.05-1.94	0.021	1.22	0.91-1.64	0.188
Gender
Female	1			1
Male	1.06	0.74-1.51	0.76	1.02	0.71-1.45	0.934
Tumor location
Head	1			1
Body/tail	1.26	0.73-2.16	0.406	1.66	0.96-2.86	0.07
Operation type
Whipple	1			1
Distal pancreatectomy	0.88	0.44-1.73	0.704	1.56	0.81-2.99	0.184
Total pancreatectomy	0.56	0.14-2.27	0.417	0.88	0.28-2.79	0.832
En bloc resection	1.73	0.54-5.46	0.354	1.92	0.61-6.08	0.267
Adjuvant therapy
Chemoradiation	1			1
Chemotherapy	1.09	0.67-1.79	0.722	1.14	0.71-1.83	0.587
Radiation	0.73	0.1-5.32	0.758	0.98	0.24-4.04	0.98
None	1.89	1.26-2.84	0.002	1.55	1.02-2.37	0.041
Resection margin
Negative	1			1
Positive	1.99	1.35-2.94	0.001	1.38	0.93-2.06	0.114
Perineural invasion
Negative	1			1
Positive	1.22	0.79-1.88	0.372	0.93	0.62-1.41	0.736
Peripancreatic extension
Negative	1			1
Positive	2.23	1.27-3.91	0.005	2	1.16-3.45	0.013
TNM stage
I-IIA	1			1
IIB-IV	2	1.33-3.02	0.001	1.87	1.25-2.8	0.002
Tumor grade
I	1			1
II-III	2.43	1.34-4.42	0.004	2.24	1.28-3.92	0.005
LN examined (18 vs 7.5)	1.21	0.95-1.55	0.132	1.4	1.09-1.81	0.012
LN positive (4 vs 0)	1.52	1.26-1.83	0	1.57	1.3-1.9	< 0.001
LN ratio (0.29 vs 0)	1.44	1.18-1.76	0.001	1.57	1.27-1.95	< 0.001
Tumor size (3.5 vs 2.1)	1.08	0.95-1.23	0.279	1.2	1.07-1.34	0.007
CA 19-9 (378.25 vs 47.5)	1.04	1-1.07	0.075	1.02	0.99-1.06	0.238

HR: Hazards ratio; TNM: Tumor-node-metastasis; LN: Lymph node; CA: Carbohydrate antigen.